ZM Younossi et al. Hepatology 2019; 69: 564-72. This study, using Markov models for nonalcoholic steatohepatitis (NASH), estimated that there are 6.65 million adults with NASH in the U.S. and that lifetime costs will be $.222.6 billion.
Y Chang et al. Hepatology 2019; 69: 64-75. This study with 58,927 Koreans with non-alcoholic fatty liver disease (NAFLD), found that nonheavy alcohol consumption was “significantly and independently associated with worsening of noninvasive markers of fibrosis, indicating that even moderate alcohol consumption might be harmful.”
Related blog posts:
- Alcohol in the Setting of NAFLD
- Low Free Sugar Diet for NAFLD
- NAFLD Guidance from AASLD 2018
- Concise Review: Fatty Liver in Pediatrics
- Ultrasound Unreliable to Exclude Fatty Liver
- Fatty Liver Disease improved with Exercise
KA Forde et al. Hepatology 2019; 69: 270-81. This study examined screening for hepatopulmonary syndrome (HPS) in patients (n=363) evaluated for liver transplantation (LT). It found that pulse oximetry had low sensitivity for detecting HPS. Overall, 21% of the cohort had HPS. “We found that pulse oximetry essentially performed no better than chance (i.e.. a ‘coin flip’) in the discrimination of patients with HPS from all-comers.” 18% of patients with an SpO2 of 96% or higher had HPS. Based on their findings, the authors recommend that routine screening of LT candidates include ABG and contrast-enhanced echocardiograpy.